Coccidiosis | Jotup

ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

Retrieved on:

Mittwoch, Februar 7, 2024

Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Parasitism, Coccidiosis, Agriculture, Immune system, OTCQB, Bird, Parity, Poultry, Disease, FCR, Feed conversion ratio, Poultry farming

Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.

Key Points:

Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.
These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain.
ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry.
We believe these findings will facilitate and expand dialogues with potential partners in the agriculture and animal health industries,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience.

ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Retrieved on:

Dienstag, Januar 23, 2024

Biotechnology, Agriculture, Natural Resources, Health, Veterinary, Coccidiosis, Environment, Partnership, OTC, Poultry, Parity, Disease, USDA, Bird, Poultry farming

With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product.

Key Points:

With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product.
The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry.
The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis.
Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product.

Amlan International Set To Exhibit Natural Mineral Technology At International Production And Processing Expo (IPPE)

Retrieved on:

Donnerstag, Januar 11, 2024

Livestock, Health, Poultry, Salmonella, Innovation, Government, T-2 mycotoxin, Poultry World, ODC, IPSF, T-2, Research, Marketing strategy, IPPE, Coccidiosis, Animal feed

Amlan is set to showcase its commitment to advancing animal health and feed technology through multiple on-site presentations.

Key Points:

Amlan is set to showcase its commitment to advancing animal health and feed technology through multiple on-site presentations.
The Amlan team looks forward to engaging with an international audience of animal production professionals, sharing comprehensive insights into its range of mineral based feed additives with attendees, media, and fellow exhibitors at booth B15005.
The seminar will focus on Natural Solutions for Gut Health and is being hosted by Poultry World.
“Our team is looking forward to sharing the latest NeutraPath research,” said Dr. Wade Robey, President, Amlan International.

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Retrieved on:

Montag, Oktober 30, 2023

This new study will be performed under the same conditions as the previous 28-day coccidiosis challenge study, but will be carried out for the full 42-day grow out period typical in the broiler production industry.

Key Points:

This new study will be performed under the same conditions as the previous 28-day coccidiosis challenge study, but will be carried out for the full 42-day grow out period typical in the broiler production industry.
“Our coccidiosis product candidate holds potential to transform poultry health management.
Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years.
Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Retrieved on:

Dienstag, September 19, 2023

Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry.

Key Points:

Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry.
Birds treated with ZIVO’s product candidate demonstrated statistically significant improvements across all measures of broiler health examined.
Diseased chickens treated with elevated doses of ZIVO's product candidate exhibited reductions in disease-related effects to a level seen in healthy birds.
As a result, ZIVO remains confident that its novel product candidate for broiler chickens presents a disruptive solution to coccidiosis, one of the most significant challenges facing the global poultry industry.

ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food

Retrieved on:

Mittwoch, Juli 26, 2023

Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the commercialization of its proprietary algal biomass as a food or food ingredient.

Key Points:

Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the commercialization of its proprietary algal biomass as a food or food ingredient.
ZIVO has engaged an independent distributor, ZWorldwide, Inc., who will launch the product, branded ZivolifeTM, with an initial focus on North America.
ZIVO and ZWorldwide are parties to an exclusive commercial agreement that is expected to result in ongoing product sales by ZIVO.
ZIVO also announces the signing of a contract manufacturing agreement with Alimenta Algae SAC (“Alimenta Algae”) to grow and process the algal biomass at facilities previously utilized by ZIVO for development in Peru.

ZIVO Bioscience Receives $1 Million Bridge Financing

Retrieved on:

Mittwoch, April 5, 2023

Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief Executive Officer, and President, John Payne.

Key Points:

Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief Executive Officer, and President, John Payne.
ZIVO Bioscience intends to use the proceeds from this bridge financing for working capital purposes, to fund a recently launched validation study with its product candidate for the prevention and treatment of coccidiosis in broiler chickens, and to pursue additional strategic alternatives.
“I am optimistic about the future of ZIVO Bioscience due to our talented team, our thoughtful business strategy and multiple near-term milestones.
ZIVO Bioscience has commenced the comprehensive study in broiler chickens and expects to complete work to affirm the protocol of its planned coccidiosis study, including titration analysis and dosing challenges, in May.

ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Retrieved on:

Freitag, Februar 10, 2023

The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens produced questionable results due to a high disease burden among tested chickens.

Key Points:

The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens produced questionable results due to a high disease burden among tested chickens.
Despite efforts to titrate the inoculum in advance to assure an appropriate study environment, the disease burden was elevated far beyond naturally occurring or target study conditions.
"ZIVO remains focused on a biotech business strategy prioritizing its product candidate for the treatment of coccidiosis in chickens and continues work with the USDA for final approval.
We believe this strategy will result in the best opportunity to optimize value through achieving sustainable revenue in the shortest timeframe possible.

Amlan® International’s Phylox® Honored With 2023 IPPE New Product Showcase “Best of the Best” in Live Production Award

Retrieved on:

Dienstag, Februar 7, 2023

The accolade, awarded at the recent International Production & Processing Expo (IPPE), recognized Amlan for its launch of Phylox, a natural, non-pharmaceutical coccidiosis solution for live production programs including those producers that need to meet the demand for no-antibiotic-ever (NAE) production.

Key Points:

The accolade, awarded at the recent International Production & Processing Expo (IPPE), recognized Amlan for its launch of Phylox, a natural, non-pharmaceutical coccidiosis solution for live production programs including those producers that need to meet the demand for no-antibiotic-ever (NAE) production.
Amlan is thankful for the opportunity to share our new product mode-of-action video with the global IPPE audience and we're honored to stand alongside other industry innovators.
To view Amlan’s video submission for the “Best of the Best” in Live Production Award on Phylox, please visit https://www.youtube.com/watch?v=c3JwnAuDdSg .
Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.

Amlan International to Showcase Natural Mineral Technology at International Production and Processing Expo (IPPE)

Retrieved on:

Donnerstag, Januar 12, 2023

Last year at IPPE, Amlan expanded its product portfolio with the launch of Phylox (available in select international markets).

Key Points:

Last year at IPPE, Amlan expanded its product portfolio with the launch of Phylox (available in select international markets).
Phylox is a research-backed, natural alternative to anticoccidial drugs that supports gut health naturally thus improving productivity and, in turn, driving producers' profits.
Vertical integration allows Amlan to leverage Oil-Dri's mineral science expertise to develop novel, natural feed additives.
Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC).